FINWIRES · TerminalLIVE
FINWIRES

Barclays Cuts BioMérieux's PT, Affirms Equalweight Rating

By

Barclays on Wednesday decreased the price target for in vitro diagnostics company BioMérieux (BIM.PA) to 80.00 euros from 90.00 euros and reiterated its equal weight rating.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Related Articles